Allogene Therapeutics Stock Price - ALLO

24.245
0.005 (0.02%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Allogene Therapeutics Inc ALLO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.63 2.67% 24.24 23.20 24.30 23.51 23.61 16:04:01
Bid Price Ask Price Spread Spread % News
23.71 26.19 2.48 9.47% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,217 317,752 $ 23.76 $ 7,551,050 522,796 21.25 - 33.80
Last Trade Time Type Quantity Stock Price Currency
16:04:25 26 $ 24.245 USD

Allogene Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.95B 121.90M $ -211.81M -7.35 - 117.94M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 6.00 3.20%

more financials information »

Allogene Therapeutics News

Loading Messages....

Latest ALLO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALLO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week24.0624.3022.8523.49355,9610.180.75%
1 Month25.2025.809921.2523.22511,419-0.96-3.81%
3 Months26.4633.3921.2526.33636,132-2.22-8.39%
6 Months26.5933.8021.2527.13486,595-2.35-8.84%
1 Year31.2433.8021.2527.56460,812-7.00-22.41%
3 Years22.0035.5521.2527.28508,1182.2410.18%
5 Years22.0035.5521.2527.28508,1182.2410.18%

Allogene Therapeutics Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.


Your Recent History
NASDAQ
ALLO
Allogene T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.